|
Laboratory Services Section, Department of Transfusion Medicine Core Report
|
Research Initiative
|
FDA
|
CC
|
Laboratory Services Section, Department of Transfusion Medicine Core Report
|
|
Leprosy Research Support in Armadillos (Dasypus Novemcinctus)
|
Other
|
HRSA
|
NIAID
|
The Leprosy Research Support and Maintenance of an Armadillo Colony – Post Genome Era interagency agreement provides standardized research reagents to investigators worldwide to assist in the development of skin test antigens used to detect leprosy. This agreement supports collaborative research to continuously improve biochemical, microbiological, and immunological models for leprosy research in an effort to provide the most up-to-date resource and expertise for mycobacterial researchers.
|
|
Leveraging Novel Technologies for Chronic Disease Management for Aging Underserved Populations
|
Research Initiative
|
OASH
|
NHLBI
|
HHS Office of the Assistant Secretary for Health (OASH), in partnership with other federal agencies, has issued a Request for Information (RFI) to gain a more comprehensive understanding from our stakeholders regarding innovative solutions to chronic disease management. The RFI is focused on how to leverage novel technologies to optimize compliance with evidence-based standards of care in disease states that cause significant morbidity and mortality in aging populations in underserved areas. The RFI also seeks to identify opportunities to strengthen the U.S. healthcare system through public-private partnerships in data sharing, comprehensive analytics including AI, and other potential mechanisms.
|
|
LGBT Healthy People 2030 Working Group (LGBT HP 2030)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, ACL, AHRQ, ATSDR, BARDA, CDC, CMS, FDA, HRSA, IHS, OS, Office of the Surgeon General (OSC), SAMHSA
|
OD/DPCPSI/SGMRO, NCI, NEI, NHLBI, NIA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIMH, NINDS
|
Healthy People provides science-based national goals and objectives with 10-year targets designed to guide national health promotion and disease prevention efforts to improve the health of all Americans. As part of its mission, Healthy People has established benchmarks and monitored progress over three decades in order to (1) engage multiple sectors to strengthen policies and improve practices that are driven by the best available evidence and (2) to increase public awareness of the determinants of health, disease, and disability and the opportunities for progress.
|
|
Linkage of Surveillance, Epidemiology, End Results data to Centers for Medicare and Medicaid data (SEER-CMS)
|
Resource Development
|
CMS
|
NCI
|
SEER registry data (e.g., cancer diagnosis date, site, histology) are individually linked to CMS data (e.g., enrollment, claims, assessments and surveys) using personally identifiable information. The data on the matching cancer cases are pulled together with CMS data on non-cancer controls (e.g., individuals not known to have a cancer diagnosis who reside in a SEER area) to create four research data resources: SEER-Medicare, SEER-Medicare Health Outcomes Survey (SEER-MHOS), SEER-Consumer Assessment of Healthcare Providers and Systems (SEER-CAHPS) and SEER-Medicaid. The SEER-CAHPS data set is a resource for quality of cancer care research based on a linkage between the NCI's Surveillance, Epidemiology and End Results (SEER) cancer registry data and the Centers for Medicare Medicaid Services' (CMS) Medicare Consumer Assessment of Healthcare Providers and Systems (CAHPS®) patient surveys. The SEER-MHOS is a data resource for cancer health outcomes research. It is based on a linkage between the NCI's Surveillance, Epidemiology and End Results (SEER)External Web Site Policy cancer registry data and the Centers for Medicare Medicaid Services' (CMS) Health Outcomes Survey (HOS).
|
|
Liquid Biopsy Working Group (LBWG)
|
Committee, Work group, Advisory group, or Task Force
|
CMS, FDA
|
NCI
|
This transagency work group meets monthly to review progress in liquid biopsy toward early detection of cancer. Members from several NCI Divisions and Offices, CMS and FDA participate in the meeting. As part of this committee, experts from the extramural community are invited to speak about latest progress in liquid biopsy.
|
|
Logical Observation Identifiers Names and Codes (LOINC)
|
Resource Development
|
AHRQ, CDC, CMS, HRSA, IHS, IOS
|
NLM
|
This activity supports the maintenance, distribution, and continued development of LOINC®, a set of universal codes and names to identify laboratory and other clinical observations which facilitates the exchange and pooling of clinical results for clinical care, outcomes management, public health, and research. NLM has a contract with Regenstrief to distribute the LOINC vocabulary through the UMLS and to cover some special projects to enhance parts of the LOINC vocabulary. Regenstrief creates and maintains the LOINC database and supporting documentation, and the RELMA mapping program. AHRQ, CDC, CMS, HRSA, HIS and IOS use LOINC. The past and current contract allows for tasks to be assigned to Regienstrief to review and enhance portions of the LOINC vocabulary based on special or new topic areas. In the past the collaborators have asked NLM to designate a special task/ work to be done through an MOU or IAA; the collaborators provide funding for the special task.
|
|
Long-Term Impact of Military-Relevant Brain Injury (LIMBIC) Consortium/Chronic Effects of Neurotrauma Consortium (GENC) Government Steering Committee
|
Committee, Work group, Advisory group, or Task Force
|
ACL
|
NINDS
|
The goals of LIMBIC-CENC are to examine the immediate effects of concussion on the brain as well as those later in life (e.g. risk for dementia), to identify the best treatments for concussion. and to disseminate this information to service members and relevant stakeholders.
|
|
Lower Limb Prosthetics Research Standards Working Group
|
Committee, Work group, Advisory group, or Task Force
|
ACL, AHRQ, CMS, FDA
|
NICHD, NIDDK, OD
|
This working group helps to determine research standards for lower limb prosthetics.
|
|
Lupus Clinical Trials
|
Research Initiative
|
FDA
|
OD/OIR, NIAMS
|
Lupus Clinical Trials
|